Delay in bladder cancer surgery decreases survival

Article

Bladder cancer patients whose surgery was delayed more than 3 months after diagnosis were more likely to die from their disease than were patients whose surgery was performed sooner, according to a recent study by researchers at the University of Michigan Comprehensive Cancer Center, Ann Arbor.

Bladder cancer patients whose surgery was delayed more than 3 months after diagnosis were more likely to die from their disease than were patients whose surgery was performed sooner, according to a recent study by researchers at the University of Michigan Comprehensive Cancer Center, Ann Arbor.

The study, published in the Journal of Urology (2006; 175:1262-7), followed 214 patients diagnosed with muscle-invasive bladder cancer and treated with radical cystectomy. Thirty-nine percent of patients without a 93-day delay to surgery died compared with 54% of patients whose surgery was delayed more than 93 days. The patients whose surgery was delayed lived only 1 year on average, and their 3-year survival rate was 38%, compared with the 3-year survival rate of 51% for patients whose surgery was not delayed.

The most common reason for delay was scheduling issues. Less-frequent reasons were patients seeking multiple opinions, misdiagnosis, or patients reluctant to be treated.

“Most of these causes for delaying surgery are potentially reversible, and physicians-despite busy schedules and the need for second opinions-need to be diligent about coordinating appointments and information in a timely way,” said lead author Cheryl Lee, MD.

Related Videos
Kevin M. Wymer, MD
Video 7 - "Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer"
Video 6 - "Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape"
Video 5 - "Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer"
Video 4 - "Androgen Receptor Signaling and Its Role in Driving Prostate Cancer Metastasis"
Video 3 - "Treatment Selection in Metastatic and Castration Resistant Prostate Cancer: Optimizing Outcomes and Preserving Patient Quality of Life"
Video 2 - "Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer"
Video 1 - "Metastatic Prostate Cancer: Background and Patient Prognosis"
Related Content
© 2024 MJH Life Sciences

All rights reserved.